Released Nov 5, 2026, before the open
10-Q filed Nov 5, 2026, 36 days after period end · 0001534120-26-000057
Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company focused on developing therapies targeting the IL-1β pathway for immune-mediated inflammatory diseases, today reported financial results for the third quarter of 2026 and provided a business update.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $249.00K | $236.00K |
| Net Income | -$18.95M | -$30.63M |
Avalo Therapeutics, Inc. · CIK 1534120 · Engraved from SEC EDGAR
| $23.04M |
| -$5.23M |
| EPS Diluted | -$0.34 | -$2.19 | -$2.83 | -$26.83 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Avalo Therapeutics reported third quarter 2026 financial results and a business update in a press release dated November 5, 2026.¶1
Cash, cash equivalents and investments were $462.8 million as of September 30, 2026, expected to fund operations into 2029.¶1¶2
Research and development expenses were $15.0 million for the third quarter of 2026, an increase of $1.4 million from the third quarter of 2025.¶3
Net loss was $18.9 million for the third quarter of 2026, a decrease of $11.7 million from the third quarter of 2025, or $0.34 per basic and diluted share.¶4
Avalo expects FDA feedback on its proposed abdakibart development plan by year-end 2026 and plans to initiate the Phase 3 program in the first half of 2027.¶5